Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 28 08 2023
received: 29 06 2023
accepted: 11 09 2023
medline: 7 11 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Cystic hypersecretory lesions are rare and include atypical cystic hypersecretory hyperplasia (A-CHH) and cystic hypersecretory carcinoma in situ (CHC-IS). Despite detailed morphological descriptions, little is known about the genetic landscape of these lesions. We identified four A-CHH and three CHC-IS from 2010 to 2022. Patients ranged from 39 to 65 (median 49) years. All lesions showed characteristic cystically dilated ducts with colloid-like secretions lined by enlarged cells with hyperchromatic nuclei and at least moderate cytological atypia. CHC-IS was remarkable for a greater degree of intraductal proliferation, typically with a micropapillary pattern. Four patients had concurrent ipsilateral invasive carcinoma. Next-generation sequencing (104 cancer-associated genes) was successful in four, showing variants in TP53 (3), KEAP1 (1) and MDM2 (1). p53 immunohistochemistry was concordant with molecular results with mutant-pattern staining in three TP53-mutants and wild-type in one. In three cases where sequencing failed, one showed mutant p53 staining, one was wild-type and one had no remaining lesion. The combined molecular and immunohistochemical results demonstrated p53 alterations in one A-CHH and three CHC-IS. Based on this limited cohort, atypical cystic hypersecretory lesions appear to commonly harbour TP53 alterations. To our knowledge, this is the first study to characterise molecular alterations in this rare subset of breast lesions.

Identifiants

pubmed: 37771083
doi: 10.1111/his.15056
doi:

Substances chimiques

Kelch-Like ECH-Associated Protein 1 0
Tumor Suppressor Protein p53 0
NF-E2-Related Factor 2 0
TP53 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

989-993

Subventions

Organisme : Vickery-Colvin Intradepartmental Grant

Informations de copyright

© 2023 John Wiley & Sons Ltd.

Références

Rosen PP, Scott M. Cystic hypersecretory duct carcinoma of the breast. Am. J. Surg. Pathol. 1984; 8; 31-41.
Guerry P, Erlandson RA, Rosen PP. Cystic hypersecretory hyperplasia and cystic hypersecretory duct carcinoma of the breast. Pathology, therapy, and follow-up of 39 patients. Cancer 1988; 61; 1611-1620.
Galman L, Catalano J, Cordero A, Akram M, Brogi E. Secretory and cystic hypersecretory changes at breast core needle biopsy: clinical, radiologic and pathologic findings in 67 cases. Mod. Pathol. 2013; 26; 41A.
D'Alfonso TM, Ginter PS, Liu YF, Shin SJ. Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. Am. J. Surg. Pathol. 2014; 38; 45-53.
Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2010; 2; 146-158.
Skalova A, Ryska A, Kajo K, di Palma S, Kinkor Z, Michal M. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases. Histopathology 2005; 46; 43-49.
Herrmann ME, McClatchey KD, Siziopikou KP. Invasive cystic hypersecretory ductal carcinoma of breast: a case report and review of the literature. Arch. Pathol. Lab. Med. 1999; 123; 1108-1110.
Lee JS, Lee YJ. Invasive cystic hypersecretory carcinoma of the breast: a case report. J. Korean Med. Sci. 2004; 19; 149-151.
Park JM, Seo MR. Cystic hypersecretory duct carcinoma of the breast: report of two cases. Clin. Radiol. 2002; 57; 312-315.
Resetkova E, Padula A, Albarraccin CT, Sneige N. Pathologic quiz case: a large, ill-defined cystic breast mass. Invasive cystic hypersecretory duct carcinoma. Arch. Pathol. Lab. Med. 2005; 129; e79-e80.
Shin SJ, Rosen PP. Carcinoma arising from preexisting pregnancy-like and cystic hypersecretory hyperplasia lesions of the breast: a clinicopathologic study of 9 patients. Am. J. Surg. Pathol. 2004; 28; 789-793.
Song SW, Whang IY, Chang ED. Cystic hypersecretory ductal carcinoma of the breast: a rare cause of cystic breast mass. Jpn. J. Radiol. 2011; 29; 660-662.
Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490; 61-70.
Shahbandi A, Nguyen HD, Jackson JG. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer 2020; 6; 98-110.

Auteurs

Baris Boyraz (B)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Dennis C Sgroi (DC)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

A John Iafrate (AJ)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Melinda F Lerwill (MF)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH